Skip to content

Christopher Poppe

9 papers in the library · 28 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

717. Clinical trials, ethical dimensions, and the pathway of MDMA-assisted therapy in PTSD

The International Journal of Neuropsychopharmacology September 1, 2026 C Poppe, D Repantis

Abstract Background MDMA-assisted therapy (MDMA-AT) has shown promise for treatment-resistant post-traumatic stress disorder (PTSD), leveraging unique affective effects such as enhanced trust, empathy, and social connectedness. Despite preliminary efficacy, ethical challenges in clinical trials may directly affect regulatory approval and future clinical implementation. Aims & Objectives The...

Klassische Halluzinogene in der Behandlung von Suchterkrankungen – Ein narrativer Überblick

Suchttherapie August 1, 2026 Yann David Kippe, C. Poppe, Dimitris Repantis et al.

Zusammenfassung Klassische Halluzinogene („Psychedelika“) wie Lysergsäurediethylamid (LSD), Psilocybin, N,N-Dimethyltryptamin (DMT) und 5-Methoxydimethyltryptamin (5-MeO-DMT) werden zurzeit wieder als potenzielle Behandlungsoptionen bei Substanzgebrauchsstörungen untersucht. Psychedelika entfalten ihre Wirkung über eine Aktivierung von serotonergen 5HT-2a Rezeptoren im zentralen Nervensystem,...

If you respect someone, let them go? Personal autonomy and physical safety in psychedelic treatments

JME Practical Bioethics July 1, 2026 Christopher Poppe, Chiara Caporuscio, Dimitris Repantis

Psychedelic treatments hold significant therapeutic promise for various psychiatric conditions. However, their unique therapeutic setting with psychedelic substance dosing sessions presents a particular ethical issue concerning patient autonomy. This article explores the ethics of limiting personal autonomy and freedom of movement during dosing sessions due to concerns for physical safety....

Attitudes and perceptions of psychedelic therapy among clinical trial participants with alcohol use disorder: a mixed-method study

Psychopharmacology June 10, 2026 Julian Kirsch, Christopher Poppe, Anne Beck et al.

BACKGROUND: Alcohol use disorder (AUD) remains a major global health concern, with high morbidity and mortality and limited long-term treatment success. Psychedelic therapy has re-emerged as a potential novel intervention for AUD, yet little is known about how affected individuals perceive such treatments. METHODS: This mixed-method study explored attitudes and perceptions of psychedelic...

Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment-Resistant Depression: A Qualitative Study.

Brain and Behavior June 1, 2026 Christopher Poppe, Liisa Lyck, Laura Bechtold et al. 1 citation

Expectations strongly shape participant experiences in clinical trials, contributing to placebo effects that complicate interpretation of outcomes. While quantitative tools exist to measure expectations, their subjective and multidimensional nature, especially for individuals with treatment-resistant depression (TRD), remains underexplored. This study aimed to explore the motivations and...

Mitigating Ethical Issues in Training for Psychedelic Therapy

Neuroethics April 1, 2025 Christopher Poppe, Daniel Villiger, Dimitris Repantis et al. 9 citations

Abstract In the present paper, we analyze the ethical issues in training for psychedelic therapy and discuss mitigation strategies for these issues. Specifically, after describing models of psychedelic training, we describe four problems of psychedelic training: (1) the imperative for comprehensive training due to vulnerability of participants, (2) psychedelic but not psychotherapeutic...

Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review

Psychological Medicine 2025 Chiara Caporuscio, Christopher Poppe, Astrid Gieselmann et al. 9 citations

Abstract Based on promising preliminary results from clinical trials, it seems likely that psychedelic substances (classic serotonergic psychedelics, such as psilocybin, and entactogens, such as MDMA) will be introduced into psychiatry as psychedelic-assisted therapy. This also raises a range of ethical questions that urgently need to be addressed before widespread roll-out in society. This...

Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.

Current Topics in Behavioral Neurosciences November 8, 2024 Christopher Poppe, Dimitris Repantis 9 citations

In this chapter, we provide an overview of ethical aspects of psychedelic-assisted treatments in the areas of clinical ethics, research ethics, and at the intersection of psychedelic medicine and society. In contrast to earlier psychedelic research, nowadays medical ethics have been firmly established as a discipline regulating patient-physician relationships which highlight the importance of...